Stockscreener 앱 받기
1.56
2.50%
-0.04
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Acrivon Therapeutics Inc (ACRV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acrivon Therapeutics Inc (ACRV) Balance Sheet - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.570|Chg%:-0.030 - TradingKey
TradingKey - TradingKey
Acrivon Therapeutics Inc (ACRV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acrivon Therapeutics Inc (ACRV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acrivon Therapeutics Inc (ACRV) Institutional Confidence - TradingKey
Acrivon Therapeutics Inc (ACRV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acrivon Therapeutics Inc (ACRV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acrivon Therapeutics Inc (ACRV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.600|Chg%:-0.070 - TradingKey
Form 4 Acrivon Therapeutics Inc For: 24 July By Investing.com - Investing.com South Africa
Acrivon Therapeutics CLO Mary Miller sells $1,008 in company stock - Investing.com
Acrivon Therapeutics CLO Mary Miller sells $1,008 in company stock By Investing.com - Investing.com Australia
Insider tax-withholding share sale at Acrivon Therapeutics (NASDAQ: ACRV) - Stock Titan
Acrivon Therapeutics (ACRV) Slips Slightly, Holding Near Key Support ZoneRegression Channel - dars.gov.et
ACRV Stock Price, Quote & Chart - ChartMill
Why Is Acrivon Therapeutics (NASDAQ:ACRV) Fueling Nasdaq Talk? - Kalkine Media
Acrivon Therapeutics (ACRV) Holds Steady Near Support Amid Low-Volume TradingVolume Spike Alerts - dars.gov.et
Acrivon highlights AP3 platform and clinical pr... - Pluang
Acrivon to Present Tumor Shrinkage and Partial Responses at AACR - Stock Titan
Trading Systems Reacting to (ACRV) Volatility - Stock Traders Daily
Acrivon Therapeutics trades below cash value de... - Pluang
Acrivon Therapeutics: Priced For Failure, Built For Precision (NASDAQ:ACRV) - Seeking Alpha
ACRVAcrivon Therapeutics Inc Options - Finviz
Price to book forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Enterprise value to EBITDA forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Price to earnings forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Acrivon Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRV) - TradingView
ACRV Forecast — Price Target — Prediction for 2027 - TradingView
Acrivon Therapeutics (ACRV) Slips 2.47% in Low-Volume Trade, Testing Key Support at $1.5Sector ETF Flow - dars.gov.et
Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52 - Stock Titan
Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52 - Stock Titan
Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options - Stock Titan
Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike - Stock Titan
Acrivon Therapeutics (ACRV) director granted options on 20,275 shares - Stock Titan
Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds - Stock Titan
Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 - Stock Titan
Acrivon Shareholders Approve Expanded Equity Plan and Directors - The Globe and Mail
Acrivon Therapeutics Stockholders Approve Amended 2022 Equity Incentive Plan and Elect New Directors – June 2026 - Minichart
Acrivon Therapeutics shareholders approve equity plan changes and director elections - Investing.com UK
Acrivon Therapeutics shareholders approve equity plan changes and director elections By Investing.com - Investing.com India
Acrivon amends equity plan, shareholders approve 3,000,000-share increase - TradingView
Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):